Orchestra BioMed's AVIM Therapy Takes Center Stage at HRX Live 2026
Event summary
- Orchestra BioMed's AVIM Therapy featured in two sessions at HRX Live 2026, September 18-20.
- Sponsored roundtable to focus on Orchestra BioMed's collaboration with Medtronic for AVIM Therapy development.
- Panel session to explore expanding role of permanent pacing beyond bradycardia, including AVIM Therapy.
- BACKBEAT Global Pivotal Trial nearing enrollment completion.
- AVIM Therapy has FDA Breakthrough Device Designations for uncontrolled hypertension in pacemaker-indicated patients.
The big picture
Orchestra BioMed's AVIM Therapy is positioning itself as a transformative treatment for uncontrolled hypertension, leveraging strategic partnerships with industry leaders like Medtronic. The therapy's inclusion in high-profile sessions at HRX Live 2026 underscores growing recognition within the electrophysiology community. With FDA Breakthrough Device Designations and a near-complete pivotal trial, AVIM Therapy is poised to address a significant unmet need in cardiovascular care.
What we're watching
- Clinical Trial Progress
- How the completion of the BACKBEAT Trial will impact AVIM Therapy's regulatory path and commercialization prospects.
- Strategic Partnerships
- Whether the Orchestra BioMed-Medtronic collaboration can serve as a model for accelerating medical device innovation.
- Market Expansion
- The pace at which AVIM Therapy can penetrate the uncontrolled hypertension market, estimated at 7.7 million patients in the U.S.